Article Sidebar

PDF
Published: 2023-12-31
Abstract Views: 186
Views PDF: 153
DOI: https://doi.org/10.52852/tcncyh.v173i12E13.1723
Issue
Vol. 173 No. 12E13 (2023)
Section
Các bài báo
How to Cite
Quyen, L. H., & Mai, T. T. C. (2023). 2. Correlation between plasma renin concentration and plasma renin activity assays on the Maglumi 800 chemiluminescence immunoassay analyzer. Journal of Medical Research, 173(12E13), 9-17. https://doi.org/10.52852/tcncyh.v173i12E13.1723

2. Correlation between plasma renin concentration and plasma renin activity assays on the Maglumi 800 chemiluminescence immunoassay analyzer

Luong Hue Quyen, Tran Thi Chi Mai

Main Article Content

Abstract

The ratio of plasma aldosterone concentration to plasma renin activity (PAC/PRA) is the most common screening test for primary hyperaldosteronism, but it is not standardized among laboratories. We evaluated the correlation between plasma renin concentration (PRC) and plasma renin activity (PRA), and then PAC/PRC and PAC/PRA ratios on Maglumi 800 immunoassay analyzer. Forty-five plasma samples from volunteers were collected. PRC, PRA and PAC were measured by Maglumi 800 - a fully-auto chemiluminescence immunoassay analyzer. Correlation between plasma renin concentration (PRC) and plasma renin activity (PRA), and then PAC/PRC and PAC/PRA ratios were determined by regression analysis. PRC and PRA showed a good correlation (r = 0.88). The PAC/PRC and PAC/PRA ratios have a similar relationship (r = 0.757). Because of the advantages of the procedure and the independence of PRC from endogenous angiotensinogen levels, PRC may be used preferentially over PRA as high throughput screening tool.

Article Details

Keywords

Plasma renin activity (PRA), plasma renin concentration (PRC), plasma aldosterone concentration to plasma renin activity ratio (PAC/PRC), plasma aldosterone concentration to plasma renin concentration ratio (PAC/PRA).

References

1. MC Chapell. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016; 310(2), H137-52.
2. Hartman D, Sagnella GA, Chesters CA, Macgregor GA . Direct Renin Assay and Plasma Renin Activity Assay Compared. Clinical Chemistry. 2004; 50(11), 2159 - 2161.
3. Sealey JE, Trenkwalder P, Gahnem F, Catanzaro D, Laragh JH. Plasma renin methodology: inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with the traditional enzymatic plasma renin activity assay. Am J Hypertens. 1995; 13, 27-30.
4. Cartledge S, Lawson N. Aldosterone and renin measurements. Ann Clin Biochem. 2000; 37, 262-278.
5. Leckie BJ, Birnie G, Carachi R. Renin in Wilms’ tumour: prorenin as an indicator. J Clin Endocrinol Metab. 1994; 79, 1742-1746.
6. Sealey JE, Goldstein M, Pitarresi T, Kudlak TT, Glorioso N, Fiamengo SA, Laragh JH. Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. J Clin Endocrinol Metab. 1988; 66, 974-978.
7. Racz K, Pinet F, Gasc JM, Guyene TT, Corvol P. Coexpression of renin, angiotensinogen, and their messenger ribonucleic acids in the adrenal gland. J Clin Endocrinol Metab. 1992;75, 730, 7.
8. Jonathan H.S, Mohammed A.M, Roberta J.D. Physiology, Aldosterone. STATPEARLS. 2022.
9. Perschel FH, Schemer R, Seiler L, et al. Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays. Clin Chem. 2004; 50(9), 1650-1655.
10. Young WF Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology. 2003; 144, 2208-2213.
11. Quinkler M, Lepenies J, Diederich S et al. Primary hyperaldosteronism. Exp Clin Endocrinol Diabetes. 2002; 110, 263-271.
12. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002; 31, 619-632.
13. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 1992; 75, 259-264.
14. Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab. 2000; 85, 3266–3270.
15. Young WF Jr. Primary aldosteronism: management issues. AnnN Y Acad Sci. 2002; 970, 61–76.
16. Perschel FH, Schemer R, Seiler L et al. Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays. Clinical Chemistry. 2004; 50(9), 1650-1655.
17. Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K, Petersenn S. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. European Journal of Endocrinology. 2004; 150, 517-523.